Actimmune Side Effects Center
Medical Editor: John P. Cunha, DO, FACOEP
Actimmune (interferon gamma 1 b) is a specific interferon used to prevent infections in people with a condition called Chronic Granulomatous Disease. It is also used to treat a congenital bone disorder called osteopetrosis. It is made from human proteins. Common side effects include injection site reactions (pain/swelling/redness), diarrhea, upset stomach, nausea, or vomiting. Flu-like symptoms such as headache, tiredness, fever, chills, and muscle aches may occur, especially when you first start this medication. These symptoms usually last about 1 day after the injection and improve or go away after a few months of continued use.
The recommended dosage of Actimmune for the treatment of patients with Chronic Granulomatous Disease and severe, malignant osteopetrosis is 50 mcg/m2 (1 million IU/m2) for patients whose body surface area is greater than 0.5 m2 and 1.5 mcg/kg/dose for patients whose body surface area is equal to or less than 0.5 m2. Other drugs may affect Actimmune. Tell your doctor all medications and supplements you use. Actimmune is not recommended for use during pregnancy. It is unknown if this drug passes into breast milk. Consult your doctor before breastfeeding.
Our Actimmune (interferon gamma 1 b) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What is Patient Information in Detail?
Easy-to-read and understand detailed drug information and pill images for the patient or caregiver from Cerner Multum.
Actimmune in Detail - Patient Information: Side Effects
Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Stop using interferon gamma-1b and call your doctor at once if you have any of these serious side effects:
- fever, chills, body aches, flu symptoms;
- easy bruising or bleeding, unusual weakness;
- feeling light-headed, fainting;
- fast or uneven heart rate; or
- sudden numbness or weakness, especially on one side of the body.
Less serious side effects may include:
- problems with memory or concentration;
- weakness, tired feeling, lack of coordination;
- pain or redness where the injection was given;
- nausea, vomiting, diarrhea;
- muscle or joint pain; or
This is not a complete list of side effects and others may occur. Tell your doctor about any unusual or bothersome side effect. You may report side effects to FDA at 1-800-FDA-1088.
Read the entire detailed patient monograph for Actimmune (Interferon Gamma 1 b) »
What is Patient Information Overview?
A concise overview of the drug for the patient or caregiver from First DataBank.
Actimmune Overview - Patient Information: Side Effects
Flu-like symptoms such as headache, tiredness, fever, chills, and muscle aches may occur, especially when you first start this medication. These symptoms usually last about 1 day after the injection and improve or go away after a few months of continued use. You can reduce these side effects by injecting this medicine at bedtime and using a fever reducer/pain reliever such as acetaminophen before or after each dose. Consult your doctor or pharmacist for more information.
Remember that your doctor has prescribed this medication because he or she has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects.
Tell your doctor right away if you have any serious side effects, including: lightheadedness, fainting, mental/mood changes (e.g., confusion, depression), shaking (tremors), trouble walking, slow/fast/irregular heartbeat, shortness of breath, swelling of the ankles/feet, increasing tiredness, joint pain, butterfly-shaped rash on the face, easy bleeding/bruising, persistent nausea/vomiting, seizures, signs of infection (e.g., fever, persistent sore throat), stomach/abdominal pain, black/tarry stools, dark urine, change in the amount of urine, yellowing eyes/skin.
Get medical help right away if any of these rare but very serious side effects occur: chest/jaw/left arm pain, weakness on one side of the body, slurred speech, sudden vision changes, pain/redness/swelling of the arms/legs, calf pain/swelling that is warm to the touch, coughing up blood.
A very serious allergic reaction to this drug is rare. However, get medical help right away if you notice any symptoms of a serious allergic reaction, including: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.
This is not a complete list of possible side effects. If you notice other effects not listed above, contact your doctor or pharmacist.
In the US -
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.
Read the entire patient information overview for Actimmune (Interferon Gamma 1 b)»
What is Prescribing information?
The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.
Actimmune FDA Prescribing Information: Side Effects
The following data on adverse reactions are based on the subcutaneous administration of ACTIMMUNE (interferon gamma 1 b) at a dose of 50 mcg/m2, three times weekly, in patients with Chronic Granulomatous Disease (CGD) during an investigational trial in the United States and . Europe.
The most common adverse events observed in patients with CGD are shown in the following table:
|Percent of Patients|
|Clinical Toxicity|| ACTIMMUNE (interferon gamma 1 b)
| Injection site erythema
|Injection site pain||0||2|
Miscellaneous adverse events which occurred infrequently in patients with CGD and may have been related to underlying disease included back pain (2 percent versus 0 percent), abdominal pain (8 percent versus 3 percent) and depression (3 percent versus 0 percent) for ACTIMMUNE (interferon gamma 1 b) and placebo treated patients, respectively.
Similar safety data were observed in 34 patients with severe malignant osteopetrosis.
ACTIMMUNE (interferon gamma 1 b) has also been evaluated in additional disease states in studies in which patients have generally received higher doses ( > 100 mcg/m2/three times weekly) administered by intramuscular or subcutaneous injection, or intravenous infusion. All of the previously described adverse reactions which occurred in patients with Chronic Granulomatous Disease have also been observed in patients receiving higher doses. Adverse reactions not observed in patients with Chronic Granulomatous Disease but reported in patients receiving ACTIMMUNE (interferon gamma 1 b) (Interferon gamma-1b) in other studies include:
Cardiovascular- hypotension, syncope, tachyarrhythmia, heart block, heart failure, and myocardial infarction. Central Nervous System-confusion, disorientation, gait disturbance, Parkinsonian symptoms, seizure, hallucinations, and transient ischemic attacks.Gastrointestinal-hepatic insufficiency, gastrointestinal bleeding, and pancreatitis, including pancreatitis with fatal outcome. Hematologic-deep venous thrombosis and pulmonary embolism. Immunological- increased autoantibodies, lupus-like syndrome. Metabolic- hyponatremia, hyperglycemia and hypertriglyceridemia. Pulmonary-tachypnea, bronchospasm, and interstitial pneumonitis. Renal-reversible renal insufficiency. Other- chest discomfort, exacerbation of dermatomyositis.
No neutralizing antibodies to ACTIMMUNE (interferon gamma 1 b) have been detected in any Chronic Granulomatous Disease patients receiving ACTIMMUNE (interferon gamma 1 b) .
Children with CGD less than 3 years of age
Data on the safety and activity of ACTIMMUNE (interferon gamma 1 b) in 37 patients under the age of 3 years was pooled from four uncontrolled post-marketing studies. The rate of serious infections per patient-year in this uncontrolled group was similar to the rate observed in the ACTIMMUNE (interferon gamma 1 b) treatment groups in controlled trials. Developmental parameters (height, weight and endocrine maturation) for this uncontrolled group conformed to national normative scales before and during ACTIMMUNE (interferon gamma 1 b) therapy.
In 6 of the 10 patients receiving ACTIMMUNE (interferon gamma 1 b) therapy before age one year 2-fold to 25- fold elevations from baseline of AST and/or ALT were observed. These elevations occurred as early as 7 days after starting treatment. Treatment with ACTIMMUNE (interferon gamma 1 b) was interrupted in all 6 of these patients and was restarted at a reduced dosage in 4. Liver transaminase values returned to baseline in all patients and transaminase elevation recurred in one patient upon ACTIMMUNE (interferon gamma 1 b) rechallenge. An 11-fold alkaline phosphatase elevation and hypokalemia in one patient and neutropenia (ANC= 525 cells/mm3) in another patient resolved with interruption of ACTIMMUNE (interferon gamma 1 b) treatment and did not recur with rechallenge.
In the post-marketing safety database clinically significant adverse events observed during ACTIMMUNE (interferon gamma 1 b) therapy in children under the age of three years (n=14) included: two cases of hepatomegaly, and one case each of Stevens-Johnson syndrome, granulomatous colitis, urticaria, and atopic dermatitis.
Read the entire FDA prescribing information for Actimmune (Interferon Gamma 1 b) »
Additional Actimmune Information
Actimmune - User Reviews
Actimmune User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.